Your browser doesn't support javascript.
loading
Beyond nimodipine: advanced neuroprotection strategies for aneurysmal subarachnoid hemorrhage vasospasm and delayed cerebral ischemia.
Luzzi, Sabino; Bektasoglu, Pinar Kuru; Dogruel, Yücel; Güngor, Abuzer.
Afiliación
  • Luzzi S; Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy. sabino.luzzi@unipv.it.
  • Bektasoglu PK; Neurosurgery Unit, Department of Surgical Sciences, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. sabino.luzzi@unipv.it.
  • Dogruel Y; Department of Neurosurgery, University of Health Sciences, Fatih Sultan Mehmet Education and Research Hospital, Istanbul, Türkiye.
  • Güngor A; Department of Neurosurgery, Health Sciences University, Tepecik Training and Research Hospital, Izmir, Türkiye.
Neurosurg Rev ; 47(1): 305, 2024 Jul 05.
Article en En | MEDLINE | ID: mdl-38967704
ABSTRACT
The clinical management of aneurysmal subarachnoid hemorrhage (SAH)-associated vasospasm remains a challenge in neurosurgical practice, with its prevention and treatment having a major impact on neurological outcome. While considered a mainstay, nimodipine is burdened by some non-negligible limitations that make it still a suboptimal candidate of pharmacotherapy for SAH. This narrative review aims to provide an update on the pharmacodynamics, pharmacokinetics, overall evidence, and strength of recommendation of nimodipine alternative drugs for aneurysmal SAH-associated vasospasm and delayed cerebral ischemia. A PRISMA literature search was performed in the PubMed/Medline, Web of Science, ClinicalTrials.gov, and PubChem databases using a combination of the MeSH terms "medical therapy," "management," "cerebral vasospasm," "subarachnoid hemorrhage," and "delayed cerebral ischemia." Collected articles were reviewed for typology and relevance prior to final inclusion. A total of 346 articles were initially collected. The identification, screening, eligibility, and inclusion process resulted in the selection of 59 studies. Nicardipine and cilostazol, which have longer half-lives than nimodipine, had robust evidence of efficacy and safety. Eicosapentaenoic acid, dapsone and clazosentan showed a good balance between effectiveness and favorable pharmacokinetics. Combinations between different drug classes have been studied to a very limited extent. Nicardipine, cilostazol, Rho-kinase inhibitors, and clazosentan proved their better pharmacokinetic profiles compared with nimodipine without prejudice with effective and safe neuroprotective role. However, the number of trials conducted is significantly lower than for nimodipine. Aneurysmal SAH-associated vasospasm remains an area of ongoing preclinical and clinical research where the search for new drugs or associations is critical.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hemorragia Subaracnoidea / Nimodipina / Isquemia Encefálica / Fármacos Neuroprotectores / Vasoespasmo Intracraneal Límite: Humans Idioma: En Revista: Neurosurg Rev Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hemorragia Subaracnoidea / Nimodipina / Isquemia Encefálica / Fármacos Neuroprotectores / Vasoespasmo Intracraneal Límite: Humans Idioma: En Revista: Neurosurg Rev Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Alemania